


F1063-0967

Cat. No.:	HY-101510		
CAS No.:	613225-56-2		
Molecular Formula:	C ₂₄ H ₂₄ N ₂ O ₅ S ₂		
Molecular Weight:	484.59		
Target:	Phosphatase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (206.36 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.0636 mL	10.3180 mL	20.6360 mL
		5 mM	0.4127 mL	2.0636 mL	4.1272 mL
10 mM		0.2064 mL	1.0318 mL	2.0636 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.16 mM); Suspended solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	F1063-0967 is a Dual-specificity phosphatase 26 (DUSP26) inhibitor with an IC ₅₀ of 11.62 μM.
IC ₅₀ & Target	IC ₅₀ : 11.62 μM (DUSP26) ^[1]
In Vitro	F1063-0967 is a Dual-specificity phosphatase 26 (DUSP26) inhibitor with an IC ₅₀ of 11.62 μM. At concentration above 0.1 μM, F1063-0967 remarkably induces IMR32 cell apoptosis. F1063-0967 induces apoptosis in IMR-32 cell line with an IC ₅₀ value of 4.13 μM. F1063-0967 has no effect on HL7702 cell line, and little inhibition effect on SH-SY5Y cell line ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

The IMR-32 cells are plated in 96-well plates with 1×10^3 cells per well. After the cells are allowed to settle for 24 h, F1063-0967 (0, 10, 1, and 0.1 μM) is added. An MTT assay is performed. For cell lines HL7702 and SH-SY5Y, the cells are allowed to settle for 24 h, F1063-0967 (10 μM) is added, then MTT assays are carried out after 72 h^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ren JX, et al. Identification of novel dual-specificity phosphatase 26 inhibitors by a hybrid virtual screening approach based on pharmacophore and molecular docking. Biomed Pharmacother. 2017 May;89:376-385.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA